Clinical features of LRRK2 parkinsonism

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Haugarvoll, Kristoffer ^a   Wszolek, Zbigniew K ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b MAYO CLINIC   (United States)

Author keywords

G2019S; G2385R; Genetics; I2020T; Parkinson disease; R1441C; R1441G; R1441H; R1628P; Y1699C

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA;

ARTICLE; ASIAN; AUTOSOMAL DOMINANT DISORDER; ENZYME ACTIVITY; FAMILY; GENE IDENTIFICATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PATHOGENICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

HUMANS; MUTATION; PARKINSON DISEASE; PHOSPHOTRANSFERASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 71849086433     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70815-6     Document Type: Article

References (44)

1. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 5 (2007) 384-386
2. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 11 (2009) e22
3. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51 3 (2002) 296-301
4. Zimprich A., Muller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M., et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74 1 (2004) 11-19
5. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 4 (2004) 601-607
6. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 4 (2004) 595-600
7. Di Fonzo A., Wu-Chou Y.H., Lu C.S., van Doeselaar M., Simons E.J., Rohe C.F., et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7 3 (2006) 133-138
8. Farrer M.J., Stone J.T., Lin C.H., Dachsel J.C., Hulihan M.M., Haugarvoll K., et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 13 2 (2007) 89-92
9. Tan E.K., Tan L.C., Lim H.Q., Li R., Tang M., Yih Y., et al. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum Genet 124 3 (2008) 287-288
10. Ross O.A., Wu Y.R., Lee M.C., Funayama M., Chen M.L., Soto A.I., et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64 1 (2008) 88-92
11. Zhang Z., Burgunder J.M., An X., Wu Y., Chen W., Zhang J., et al. LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Mov Disord 24 13 (2009) 1902-1905
12. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354 4 (2006) 424-425
13. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354 4 (2006) 422-423
14. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76 4 (2005) 672-680
15. Wszolek Z.K., Pfeiffer B., Fulgham J.R., Parisi J.E., Thompson B.M., Uitti R.J., et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45 3 Pt 1 (1995) 502-505
16. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70 16 Pt 2 (2008) 1456-1460
17. Nuytemans K., Rademakers R., Theuns J., Pals P., Engelborghs S., Pickut B., et al. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet 16 4 (2008) 471-479
18. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 9 (2004) 1619-1622
19. Marti-Masso J.F., Ruiz-Martinez J., Bolano M.J., Ruiz I., Gorostidi A., Moreno F., et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord 24 13 (2009) 1998-2001
20. Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382 3 (2005) 309-311
21. Mata I.F., Hutter C.M., Gonzalez-Fernandez M.C., de Pancorbo M.M., Lezcano E., Huerta C., et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics 10 4 (2009) 347-353
22. Simon-Sanchez J., Marti-Masso J.F., Sanchez-Mut J.V., Paisan-Ruiz C., Martinez-Gil A., Ruiz-Martinez J., et al. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 21 11 (2006) 1954-1959
23. Ross O.A., Spanaki C., Griffith A., Lin C.H., Kachergus J., Haugarvoll K., et al. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 15 6 (2009) 466-467
24. Lesage S., Condroyer C., Lannuzel A., Lohmann E., Troiano A., Tison F., et al. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. J Med Genet 46 7 (2009) 458-464
25. Wszolek Z.K., Vieregge P., Uitti R.J., Gasser T., Yasuhara O., McGeer P., et al. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia: longitudinal observations. Parkinsonism Relat Disord 3 3 (1997) 125-139
26. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128 Pt 12 (2005) 2786-2796
27. Infante J., Rodriguez E., Combarros O., Mateo I., Fontalba A., Pascual J., et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 395 3 (2006) 224-226
28. Hulihan M.M., Ishihara-Paul L., Kachergus J., Warren L., Amouri R., Elango R., et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case- control genetic study. Lancet Neurol 7 7 (2008) 591-594
29. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7 7 (2008) 583-590
30. Haugarvoll K., and Wszolek Z.K. PARK8 LRRK2 parkinsonism. Curr Neurol Neurosci Rep 6 4 (2006) 287-294
31. Zabetian C.P., Hutter C.M., Yearout D., Lopez A.N., Factor S.A., Griffith A., et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79 4 (2006) 752-758
32. Elbaz A. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Lancet Neurol 7 7 (2008) 562-564
33. Ishihara L., Warren L., Gibson R., Amouri R., Lesage S., Durr A., et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63 9 (2006) 1250-1254
34. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., et al. Lrrk2 and Lewy body disease. Ann Neurol 59 2 (2006) 388-393
35. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59 2 (2006) 315-322
36. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., and Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78 6 (2007) 626-628
37. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 6 (2005) 918-921
38. Hasegawa K., Stoessl A.J., Yokoyama T., Kowa H., Wszolek Z.K., and Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15 4 (2009) 300-306
39. Fung H.C., Chen C.M., Hardy J., Singleton A.B., and Wu Y.R. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6 (2006) 47
40. Chan D.K., Ng P.W., Mok V., Yeung J., Fang Z.M., Clarke R., et al. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients. J Neural Transm 115 9 (2008) 1275-1277
41. Yu L., Hu F., Zou X., Jiang Y., Liu Y., He X., et al. LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China. Brain Res 1296 (2009) 113-116
42. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., et al. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155 (2007) 208-219
43. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16 2 (2007) 223-232
44. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12 7 (2009) 826-828